

Sebastian A. Lewandowski

Karolinska Institute, MBB, Stockholm, Sweden.
sebastian.lewandowski@ki.se



Education

- 2005 **PhD in Molecular Biology - Nencki Institute of Experimental Biology, Poland**
Thesis: Estrogen receptors influence on the p53 protein and the sensitivity to TNF α in the mammary gland carcinoma. Supervisor: Prof. Cezary Szczylik
- 1997 **MSc in Biophysics - University of Gdansk, Poland**
Thesis: The interaction between E.coli ClpX chaperonin and TrfA protein initiating the replication of an RK2 plasmid. Supervisor: Prof. Maciej Żylicz
-

Experience

- 2008 - present Post doc. Vascular Biology Div. MBB Karolinska Institute, Stockholm, Sweden.
- 2005 - 2008 Post doc. Department of Biosciences, Karolinska Institute, Stockholm, Sweden.
- 2003 - 2004 Marie Curie Fellow. INSERM 487, Institut Gustave Roussy, Paris, France.
- 2000 - 2001 Visiting Scholar. Lawrence Berkeley National Laboratory, Berkeley, USA.
-

Funding

- 2015 - 2016 Björklund fund for ALS research at Swedish Medical Association
- 2012 - 2014 Thierry Latran Foundation. Blood-brain barrier in ALS.
- 2005 - 2007 Karolinska Institute scholarship (diarienr 03940/2005).
- 2003 - 2004 Marie Curie Fellowship Association scholarship QLGA-1999-50406.
-

Research focus

Mechanisms of vascular dysfunction of blood-brain barrier and cerebral blood flow in neurodegenerative diseases with emphasis on ALS and frontotemporal dementia.

Publications

Number of publications: 13. Number of citations: 517. h index: 7.

Selected publication list (last five years)

- **Lewandowski SA ***, Fredriksson L, Lawrence DA, Eriksson U. *Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders. **Pharmacology & Therapeutics.** 167:108–119. (2016) (JIF: 11.0)*
- **Lewandowski SA ***, Nilsson I, Fredriksson L, Lönnerberg P, Muhl L, Zeitelhofer M, Adzemovic MZ, Nichterwitz S, Lawrence DA, Hedlund E, Eriksson U. *Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. **Acta Neuropathologica** 131:453-64. (2016) (JIF: 11.4)*
- Abrams MB, Nilsson I, Kjell J, **Lewandowski S**, Codeluppi S, Eriksson U, Olson L. *Response to the report, "A re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury" by Sharp et al. **Experimental Neurology.** 257:182-5. (2014) (JIF: 4.6)*
- Abrams MB, Nilsson I, **Lewandowski SA**, Kjell J, Codeluppi S, Olson L, Eriksson U. *Imatinib enhances functional outcome after spinal cord injury. **PLoS One.** 7(6):e38760. (2012) (JIF: 3.2)*

* - corresponding author